Strive Cardio for Endometrial Cancer Survivors

Prior treatment

• History of previous myocardial infarction, ischemia, or hemorrhagic stroke
• Current or recent (within last 3 months) use of hormone replacement therapy (HRT)
• Enrolled in another clinical trial or has used of any investigational drugs, biologics, or devices within 30 days prior to study enrollment

Other illness

• Absolute contraindications to exercise (i.e., acute myocardial infarction, severe orthopedic or musculoskeletal limitations)
• Medically documented history of heart disease including heart valve disease, coronary artery disease, heart failure, peripheral artery disease, aortic disease, pericardial disease, cerebrovascular disease, or deep vein thrombosis
• Medical documentation of treatment-resistant hypertension OR taking ≥2 medications to treat hypertension
• Medically documented history of cardiovascular disease including (but not limited to): bypass surgery, stent procedures, bypass grafts, or coronary angioplasty
• Medically documented or self-reported type 1 diabetes (insulin-dependents)
• Evidence of recurrent or metastatic disease
• Report of chest pain, shortness of breath, fainting, or angina pectoris
• Self-reported history of falling, fall risk

Other

• Prescriptions for or use of semaglutide (GLP-1 agonists) including name brands: Ozempic, Wegovy or Mounjaro
• Currently performing resistance training ≥2 days per week
• Currently exceeding 150 minutes of at least moderate intensity exercise per week
• Have physical disability that would limit range of motion through exercises such as sitting, standing and inability to walk one block
• Plans to move from the area
• Self-reported tobacco use in last 7 days, current smoking, current tobacco use including e-cigarettes and vaping devices
• Not suitable for study participation due to other reasons at the discretion of the investigator

• Willing and able to provide written informed consent
• Willing to comply with study procedures and available for the duration of the study
• Fluent in spoken and written English
• Women 18 years of age or older
• Documented diagnosis of Type I, stage I-IIIc endometrial cancer within the past 5 years
• Completion of current cytotoxic treatment for endometrial cancer
• Technology access (phone call access, broadband internet, Wi-Fi) for tele coaching
• Comfort and willingness to use technology (videoconferencing) throughout the study for coaching
• Pass the Physical Activity Readiness Questionnaire (PAR-Q)
• Medical clearances given by their primary provider / oncologist (if indicated by the PAR-Q)